If you are trying to understand what is Selank, the short answer is that Selank is a synthetic peptide developed as an analog of tuftsin, a naturally occurring immune-derived fragment. It has been studied primarily in laboratory and animal models as a candidate anxiolytic (anti-anxiety) and nootropic (cognition-related) compound. This overview summarizes what the peer-reviewed and preclinical research literature has actually investigated, so you can understand the science before evaluating any source.
What Is Selank at the Molecular Level
Selank is a heptapeptide, meaning it is built from a chain of seven amino acids (Thr-Lys-Pro-Arg-Pro-Gly-Pro). Its design is based on tuftsin, an endogenous peptide with documented immunomodulatory activity. Researchers extended the tuftsin sequence with a Pro-Gly-Pro tripeptide fragment, a modification reported to improve the molecule’s stability against enzymatic breakdown compared with the parent peptide. In the literature it also appears under the developmental designation TP-7.
Because it is a short peptide rather than a small-molecule benzodiazepine, Selank has been of interest to researchers examining whether peptide-based agents could produce anxiolytic-type effects in laboratory models through mechanisms distinct from classical sedative drugs.
Mechanisms Investigated in Selank Research
The mechanistic picture assembled from preclinical work is still developing, and no single pathway has been established as definitive. Several research directions appear across the literature:
- GABAergic signaling. In vitro work using IMR-32 neuroblastoma cells examined whether Selank influences genes tied to GABAergic neurotransmission. The authors reported that Selank did not directly change mRNA levels of the GABA-system genes studied, but that it appeared to modulate how GABA itself affected those genes, consistent with a hypothesis that Selank interacts with GABA-receptor signaling indirectly rather than acting as a direct receptor ligand.
- Monoaminergic and neurotrophic factors. Animal studies have described effects on brain monoamine systems and on brain-derived neurotrophic factor (BDNF), a protein involved in neuronal plasticity, particularly in the hippocampus and prefrontal cortex.
- Immune and antiviral signaling. Reflecting its tuftsin origin, studies have measured changes in the expression of chemokine, cytokine, and receptor genes following administration in mice, framing Selank as a compound with both neuroactive and immunomodulatory properties under investigation.
What the Selank Research Has Examined
Most published Selank studies are preclinical, conducted in rodent models, with a smaller number of human neuroimaging observations. It is important to read these as investigations of biological activity in research settings, not as established therapeutic outcomes.
Anxiety-Related Behavioral Models
Rodent studies have used standard behavioral paradigms, such as the elevated plus maze and social interaction tests, to examine anxiety-like behavior. One long-term rodent study of the tuftsin analog reported reductions in anxiety-phobic behavior that persisted across several weeks of repeated administration, without an accompanying change in body weight in the treated animals. These reports position Selank as a subject of interest in anxiolytic research, while remaining animal-model findings.
Cognition, Mood, and Neuroprotection Models
Other preclinical work has explored cognition- and mood-related endpoints. In a rat model of chronic ethanol exposure, researchers examined object-recognition performance and BDNF content, reporting that the peptide was associated with preserved recognition memory and altered BDNF levels during alcohol withdrawal. Additional rodent studies have investigated depression-like behavior and the aversive signs of withdrawal in dependence models. Across these papers, the peptide is described as showing anxiolytic and nootropic-type activity, but the evidence remains preliminary and largely animal-based.
Human Neuroimaging Observations
A smaller body of work has looked at Selank in people in controlled research settings. A resting-state functional MRI study in healthy participants examined how Selank and the related peptide Semax affected functional connectivity involving the amygdala and prefrontal cortex, brain regions associated with anxiety regulation and executive function. This kind of study measures brain-activity correlates rather than clinical treatment effects, and the sample was limited to healthy volunteers.
Interpreting the Selank Evidence Base
Anyone asking what is Selank should weigh several limitations in the current literature. A large share of the research originates from a small number of laboratories, much of it published in specialized Russian-language and regional journals, and many studies use modest sample sizes. The strongest signals come from rodent behavioral models, which do not automatically translate to humans. Human data are sparse and mechanistic rather than outcome-based. Taken together, the evidence is best described as early-stage and hypothesis-generating: it establishes that Selank is biologically active in these models and identifies plausible mechanisms worth further study, but it does not constitute confirmation of clinical benefit. Selank is not an approved therapeutic in the United States and is handled in these contexts strictly as a research compound.
References
- Konstantinopolsky MA, et al. Selank, a Peptide Analog of Tuftsin, Attenuates Aversive Signs of Morphine Withdrawal in Rats. Bull Exp Biol Med. 2022. doi:10.1007/s10517-022-05624-x
- Kolik LG, et al. Selank, Peptide Analogue of Tuftsin, Protects Against Ethanol-Induced Memory Impairment by Regulating BDNF Content in the Hippocampus and Prefrontal Cortex in Rats. Bull Exp Biol Med. 2019. doi:10.1007/s10517-019-04588-9
- Kolik LG, et al. Efficacy of Peptide Anxiolytic Selank During Modeling of Withdrawal Syndrome in Rats with Stable Alcoholic Motivation. Bull Exp Biol Med. 2014. doi:10.1007/s10517-014-2490-4
- Filatova E, et al. GABA, Selank, and Olanzapine Affect the Expression of Genes Involved in GABAergic Neurotransmission in IMR-32 Cells. Front Pharmacol. 2017. doi:10.3389/fphar.2017.00089
- Panikratova YR, et al. Functional Connectomic Approach to Studying Selank and Semax Effects. Dokl Biol Sci. 2020. doi:10.1134/S001249662001007X
- Czabak-Garbacz R, et al. Influence of Long-Term Treatment with Tuftsin Analogue TP-7 on the Anxiety-Phobic States and Body Weight. Pharmacol Rep. 2006. PMID:16963804
Citations retrieved from PubMed. Research Use Only. The information above is provided solely for educational and scientific reference. Selank and related compounds discussed here are research chemicals intended for laboratory research use only. They are not drugs, dietary supplements, or products for human or veterinary consumption, diagnosis, treatment, or prevention of any condition. Nothing in this article is medical advice or a recommendation for use.